The New Agents Committee (NAC) selects new anti-cancer treatments, funds any outstanding preclinical steps, and takes them into early clinical trials managed and sponsored by Cancer Research UK's Drug Development Office (DDO).
NAC members are expert in early clinical trials of novel agents and other aspects of drug development. Proposals and meetings are confidential. NAC-approved novel agents in development include: molecularly targeted small molecules, cytotoxic agents, antibodies, vaccines, viral gene therapy, immunotherapy, cell therapy, radioimmunotherapy, diagnostics and imaging agents.
The NAC is interested in proposals, from academia and industry, for scientifically-driven trials of novel unregistered anti-cancer agents, and reviews and funds:
- Exploratory/preclinical development prior to a clinical trial
- Phase I trials, including First-in-Man
- Combinations trialsof unregistered and registered agents
- Early Phase II hypothesis-testing trials
Trials, take place in UK academic clinical centres, are managed and sponsored by Cancer Research UK's Drug Development Office.
Full Proposals are subject to external, international peer review and are judged on the basis of:
- Scientific rationale and importance
- Uniqueness/novelty of the target or agent
- Significance of the proposed trial and its endpoints
- Clinical need
- Quality of data in relevant models
Other details
To view our terms of reference or our current committee membership, please view the links at the bottom of this page.
List of available schemes
The New Agents Committee currently offers the following scheme (covering both Preliminary and Full Proposals):
Committee secretariat:
Email: Kate Searle
Tel: +44 (0) 20 7121 6929
Fax: +44 (0) 20 7121 6901
Committee Members
View members of NAC...
Terms of Reference
View the Terms of Reference for NAC...
